



Oakwood

1.5.18

U.S. Nuclear Regulatory Commission  
Region III  
Materials Licensing Branch  
2443 Warrenville Road  
Suite 210  
Lisle, Illinois 60532

Re: Amendment to Materials License 21-04515-01

Dear Madam or Sir:

We wish to amend our Materials License 21-04515-01 as follows:

**ADD AUTHORIZED USER**

Caroline N. Henein, MD 35.100 35.200 and 35.300 Iodide-131 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

In support of this request we have included the following documents for your review:

- NRC License 21-16656-01 (Please see highlighted area)

If you require any additional information please contact Lindsay Vella at 313.593.7301 or at [lindsay.vella@beaumont.org](mailto:lindsay.vella@beaumont.org)

Sincerely,


David Claeys  
President, Beaumont Hospital, Dearborn  
Main 313.982.5948 | Direct 313.982.5949 | Fax 313.436.2042

RECEIVED JAN 05 2018

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Oakwood Hospital - Southshore</p>	<p>In accordance with letter dated February 22, 2017</p>	<p>4. Expiration Date: September 30, 2021</p>
<p>2. 5450 Fort St. Trenton, MI 48183</p>	<p>3. License number: 21-16056-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-11427 Reference No.:</p>



<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount of material licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>C. To be total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p>
--	---	--	--

10. Licensed material may be used or stored at the licensee's facilities located at 5450 Fort Street, Trenton, Michigan.
11. The Radiation Safety Officer (RSO) for this license is Donald J. Conn, M.D..
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
21-16656-01

Docket or Reference Number  
030-11427

Amendment No. 26

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User

Material and Use

Ronald C. Lutsic, D.O.

10 CFR 35.300

Sleman A. Khoury, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

Tai S. Kang, M.D.

10 CFR 35.100 and 35.200

Bruno F. Borin, D.O.

10 CFR 35.100 and 35.200

Josephine J. Finazzo, D.O.

10 CFR 35.100 and 35.200

James J. Kochdodan, M.D.

10 CFR 35.100 and 35.200

Reza Abghari, M.D.

10 CFR 35.100 and 35.200

David S. Yates, M.D.

10 CFR 35.100, 35.200, and 35.300

Gregory D. Olson, M.D.

10 CFR 35.100 and 35.200

Jerry W. Drake, M.D.

10 CFR 35.100, 35.200, and 35.300

Kenneth D. Bartold, M.D.

10 CFR 35.100 and 35.200

Dong Hyuck Kim, M.D.

10 CFR 35.100 and 35.200

John H. Finger, M.D.

10 CFR 35.100, 35.200, and 35.300

Sophia Roumanis, M.D.

10 CFR 35.100, 35.200, and 35.300

Donald J. Conn, M.D.

10 CFR 35.100, 35.200, and 35.300

Rob Allen Reed, M.D.

10 CFR 35.100 and 35.200

Vito A. Casano, M.D.

10 CFR 35.100 and 35.200

Michael F. Zydeck, M.D.

10 CFR 35.100 and 35.200

Jeffrey V. Tranchida, M.D.

10 CFR 35.100 and 35.200

Vladislav Jankulov, M.D.

10 CFR 35.100 and 35.200

Ashok B. Jain, M.D.


10 CFR 35.100 and 35.200

Shakuntala B. Rao, M.D.

10 CFR 35.100 and 35.200

Saleem Azad, M.D.

10 CFR 35.100 and 35.200



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

 License Number  
21-16656-01

 Docket or Reference Number  
030-11427

Amendment No. 26

Authorized User

Shameen Menon, M.D.

Caroline N. Henein, D.O.

Sharif M. Kershah, M.D.

Material and Use

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 30 millicuries)

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as required for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated April 20, 2011 (ML11120430)
- B. Letter dated September 12, 2011 (ML11284024)
- C. Letter dated March 19, 2013 (ML130944476)
- D. Letter dated March 4, 2014 (ML14072A284)
- E. Letter dated July 18, 2014 (ML14203A325)
- F. Letter dated October 6, 2014 (ML14302A755)
- G. Letter dated May 8, 2015 (ML15133A375)
- H. Letter dated February 22, 2017 (ML17060A634)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By:



 Sara A. Forster  
Region III

 Date: April 19, 2017

ORIGIN ID:DTWA (313) 593-7282  
KATHLEEN KERR  
OAKWOOD HOSPITAL & MEDICAL CENTER  
18101 OAKWOOD BLVD

SHIP DATE: 04JAN18  
ACTWGT: 1.00 LB  
CAD: 109259820/WSX13100

DEARBORN, MI 48124  
UNITED STATES US

BILL THIRD PARTY


TO REGION III  
U.S. NUCLEAR REGULATORY COMMISSION  
MATERIALS LICENSING BRANCH  
2443 WARRENVILLE RD. ST. 210  
LISLE IL 60532

549J18D40104C

(313) 593-7301  
INV.  
PO

REF:

DEPT. DBN01-831100




FRI - 05 JAN 3:00P

STANDARD OVERNIGHT

TRK# 7892 1718 5371  
0201

NA ENLA

60532  
IL-US ORD



RECEIVED JAN 05 2018

After printing this label:

1. Fold the first printed page in half and use as the shipping label.
2. Place label in shipping pouch and affix it to your shipment so that the barcode portion of the label can be read and scanned.

Shipment Summary

<b>Ship Date:</b> 1/4/2018	<b>Estimated Charge:</b> \$13.64
<b>Service Type:</b> FedEx Standard Overnight®	<b>Shipper Account #:</b> 232409380
<b>Package Type:</b> Your Packaging	
<b>Tracking Number(s):</b> 789217185371	
<b>From Address:</b> Oakwood Hospital & Medical Center Kathleen Kerr 18101 Oakwood Blvd Dearborn, MI 48124 313-593-7282	<b>To Address:</b> U.S. Nuclear Regulatory Commission Region III Materials Licensing Branch 2443 Warrenville Rd. St. 210 LISLE, IL 60532 3135937301